Nkarta (NKTX) Accounts Payables (2019 - 2026)
Nkarta's quarterly Accounts Payables came in at $1.6 million in Q1 2026, up 6.44% year-on-year from $1.5 million in Q1 2025, and down 24.08% quarter-over-quarter from $2.1 million in Q4 2025.
Nkarta has reported Accounts Payables for 8 years, with the latest figure at $1.6 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 6.44% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (up 6.44% YoY), and the FY2025 full-year result was $2.1 million, up 227.43% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.6 million, down from $2.1 million in the prior quarter.
- The five-year high for Accounts Payables was $9.5 million in Q3 2022, with the low at $638000.0 in Q4 2024.
- Average Accounts Payables over 5 years is $3.0 million, with a median of $2.1 million recorded in 2025.
- Year-over-year, Accounts Payables surged 343.85% in 2022 and tumbled 82.59% in 2024.
- Tracing NKTX's Accounts Payables over 5 years: stood at $1.8 million in 2022, then jumped by 108.12% to $3.7 million in 2023, then plunged by 82.59% to $638000.0 in 2024, then soared by 227.43% to $2.1 million in 2025, then slipped by 24.08% to $1.6 million in 2026.
- The last three Accounts Payables figures came in at $1.6 million (Q1 2026), $2.1 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 1.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 4.28 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 5.41 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 9.49 Mn |
| Jun 30, 2022 | 2.97 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 2.14 Mn |
| Jun 30, 2021 | 2.16 Mn |
| Mar 31, 2021 | 2.01 Mn |
| Dec 31, 2020 | 1.18 Mn |
| Sep 30, 2020 | 2.26 Mn |
| Jun 30, 2020 | 1.73 Mn |
| Dec 31, 2019 | 1.88 Mn |